• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Chronic Disease

High maternal egg-peanut intake not associated with reduced infant allergy

byZhenyu LiandThomas Su
September 22, 2026
in Chronic Disease, Pediatrics
Reading Time: 3 mins read
Share on FacebookShare on Twitter

1. In this randomized controlled trial, high maternal consumption of eggs and peanuts during pregnancy and lactation did not reduce IgE-mediated egg or peanut allergy in high-risk infants at one year. 

2. Maternal and infant safety outcomes were similar between groups. 

Evidence Rating Level: 1 (Excellent)

Study Rundown: Food allergy can emerge early in infancy, particularly among children with a strong family history of allergic disease. Although contemporary prevention strategies emphasize timely introduction of allergenic foods directly to infants, immune responses to food proteins may begin before solid foods are introduced. Allergens can reach the fetus through amniotic fluid and the breastfed infant through human milk, raising the possibility that greater maternal exposure during pregnancy and lactation could promote immune tolerance. Prior evidence has not supported maternal avoidance of allergenic foods, but whether deliberately increasing maternal intake could prevent food allergy remained uncertain. This trial, termed PrEggNut, found that higher consumption of egg and peanut beginning during pregnancy and continuing through early lactation did not reduce the occurrence of IgE-mediated egg or peanut allergy among infants at elevated familial risk of allergic disease. Findings were similarly neutral for individual egg and peanut allergy, sensitization, and eczema. Strengths included the multisite design, standardized allergy testing and food challenges, and consistent findings across various subgroup analyses. Important limitations included a lower-than-anticipated allergy rate, incomplete adherence, and a select high-risk population. Contemporary guidance encouraging early infant allergen introduction may also have lowered background allergy risk in both groups. Overall, increasing maternal egg and peanut consumption during pregnancy and lactation did not provide clear additional protection against infant food allergy. 

Click to read the study in NEJM 

Relevant Reading: Randomized Trial of Introduction of Allergenic Foods in Breast-Fed Infants 

RELATED REPORTS

Maternal prothrombin time may be an effective marker for neonatal sepsis risk stratification

2 Minute Medicine Rewind September 2, 2024

#VisualAbstract: Nirsevimab Reduces Hospitalization for RSV Bronchiolitis

In-Depth [randomized controlled trial]: This multisite, single-blind randomized controlled trial enrolled 2,137 pregnant women across four Australian cities between 2018 and 2024. Eligible women were less than 23 weeks pregnant with a singleton pregnancy, planned to breastfeed for at least four months, and were carrying a fetus with at least two biologic family members with medically diagnosed allergic disease. Women with egg or peanut allergy were excluded. Participants were randomized 1:1 to a high egg-peanut diet consisting of at least 6 eggs and 60 peanuts weekly or a standard diet permitting no more than 3 eggs and 30 peanuts weekly. The intervention continued from enrollment through four months postpartum while breastfeeding. The primary outcome was IgE-mediated egg or peanut allergy at one year, established using standardized skin-prick testing or medically supervised oral food challenge as needed. Primary outcome status was directly determined in 1,917 of 2,130 eligible infants (90.0%), and missing data were addressed with multiple imputation in the intention-to-treat analysis. IgE-mediated egg or peanut allergy occurred in 7.8% of infants in the high-intake group and 8.4% in the standard-diet group (adjusted relative risk [RR], 0.93; 95% confidence interval [CI] 0.69 to 1.26; P=0.65). The per-protocol analysis was concordant, with allergy occurring in 5.6% versus 6.8%, respectively (RR, 0.80; 95% CI, 0.48 to 1.35). Secondary outcomes were also similar between groups. IgE-mediated egg allergy occurred in 6.2% versus 7.2% (adjusted RR, 0.87; 95% CI, 0.62 to 1.21), while peanut allergy occurred in 2.6% of both groups (adjusted RR, 1.02; 95% CI, 0.60 to 1.76). Eczema and allergen sensitization outcomes showed no clear between-group differences. Serious adverse events occurred in 3.6% and 3.8% of participants, respectively (P=0.73), and infant anaphylaxis to egg or peanut occurred in 0.5% and 0.9% (P=0.21). The trial therefore found no evidence that substantially increasing maternal egg and peanut intake during pregnancy and early lactation reduced infant egg or peanut allergy by one year.

©2026 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc. 

Tags: allergyinfantmaternalpeanutpeanut allergy
Previous Post

The rotavirus vaccine (ROTASIIL) may reduce the incidence of hospitalization for rotavirus gastroenteritis in children

RelatedReports

Obstetric scoring systems overestimate cases of severe sepsis
All Specialties

Maternal prothrombin time may be an effective marker for neonatal sepsis risk stratification

March 25, 2026
Quick Take: Functional Outcome of Intravenous Thrombolysis in Patients With Lacunar Infarcts in the WAKE-UP Trial
Weekly Rewinds

2 Minute Medicine Rewind September 2, 2024

September 2, 2024
#VisualAbstract: Nirsevimab Reduces Hospitalization for RSV Bronchiolitis
StudyGraphics

#VisualAbstract: Nirsevimab Reduces Hospitalization for RSV Bronchiolitis

July 22, 2024
Extensive lymphadenectomy may not increase patient survival with esophageal cancer
Chronic Disease

Benralizumab associated with histologic response in eosinophilic esophagitis

July 18, 2024
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • High maternal egg-peanut intake not associated with reduced infant allergy
  • The rotavirus vaccine (ROTASIIL) may reduce the incidence of hospitalization for rotavirus gastroenteritis in children
  • Emergency department triaging decisions supported by artificial intelligence (AI) led to improved triaging accuracy and patient flow
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.